The prevalence and incidence of glaucoma in Denmark in a fifteen year period: A nationwide study

Abstract

PurposeThe purpose of the present study was to describe the prevalence, incidence and geographic variation of glaucoma in Denmark in the period from 1996 to 2011. Moreover, the aim was to identify the treatment patterns of glaucoma within the studied period. MethodsAll Danish citizens were included throughout the study period. The National Prescription Registry was used to identify all claimed prescriptions for glaucoma medication. ResultsA total of 116,592 incident glaucoma patients were identified. Average age at onset was 66 years (range: 0-105 years), 55% were women. The prevalence of glaucoma increased from 0.79% to 1.72% during the investigated period. In 2011 glaucoma affected 3.76% of the population above 50 years and 10% in patients above 80 years. The age-specific incidence rate of glaucoma seemed to be constant and the increasing prevalence was primarily attributed to an aging population. We found the highest prevalence of glaucoma in the capital region of Denmark. Within the studied period the use of prostaglandin analogs and combination drugs increased, whereas the use of β-blockers, carbon anhydrase inhibitors and parasympathomimetic drugs decreased (p<0.001). Finally, the use of α2-adrenergic agonists remained unchanged. A total of 75% of the patients were treated with two or more glaucoma medications. Data Availability Statement: Due to restrictions related to Danish law and protecting patient privacy, the combined set of data as used in this study can only be made available through a trusted third party, Statistics Denmark. This state organisation holds the data used for this study. University-based Danish scientific organisations can be authorized to work with data within Statistics Denmark and such organisation can provide access to individual scientists inside and outside of Denmark. Independent studies based on the data for the current study will require cooperation with the authors or with ConclusionsOver all, the present study is the first to assess the frequency and the development of glaucoma in Denmark over a 15-year period. We find that glaucoma affects a little less than 2% of the total population and increases with age to reach a prevalence of more than 10% amongst people above 80 years. Generally, the present study is the largest nation-wide study ever made and must be a close-to-real-life-picture of the utilization of glaucoma medication on a national scale. Our findings confirm other recent estimations on an increasing burden of glaucoma globally.

Prescription pattern of ocular hypotensive drugs in Portugal and its comparison with the European guidelines – PEM Study

“…Although both are preferred initial choices, PGAs have progressively replaced BBs as first-line drugs due to their higher efficacy, good tolerability and once-daily instillation (EGS 2014). This phenomenon has been observed in both British and Danish prescription patterns (Connor & Fraser 2014;Kolko et al 2015). In Portugal, there were still 24% of patients on monotherapy regimens without a PGA or a BB.…”

Danish teleophthalmology platform reduces optometry referrals into the national eye care system

“…This study Open access also highlights that unrecognised glaucoma is an issue that needs further awareness. [27][28][29][30][31] Three per cent of the total number of patients undergoing an optometrist comprehensive vision examination in Louis Nielsen A/S were referred for ophthalmologist review in TS in this study. This was consistent with the overall optometrist referral rate in Denmark, and can vary tremendously between countries, from 3% to 14%.…”

Comparative efficacy and safety of preserved versus preservative‐free beta‐blockers in patients with glaucoma or ocular hypertension: a systematic review

“…The most common glaucoma subtype is primary open-angle glaucoma (POAG) in which the anterior chamber angle is anatomically open (Dietze, Blair, & Havens 2020). The prevalence of glaucoma increases with age, rising to more than 10% in people older than 80 years (Vass et al 2007;Kolko et al 2015). Nearly, one in seven persons with glaucoma will go blind within 20 years, and 42% will lose sight in at least one eye (Peters, Bengtsson, & Heijl 2013;Gupta & Chen 2016).…”